These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19904491)
1. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Francisci D; Falcinelli F; Schiaroli E; Capponi M; Belfiori B; Flenghi L; Baldelli F Infection; 2010 Feb; 38(1):58-61. PubMed ID: 19904491 [TBL] [Abstract][Full Text] [Related]
2. Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study. Francisci D; Falcinelli F; Schiaroli E; Capponi M; Belfiori B; Cecchini E; Baldelli F Tumori; 2012; 98(2):220-4. PubMed ID: 22677988 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Su YC; Lin PC; Yu HC; Wu CC Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049 [TBL] [Abstract][Full Text] [Related]
5. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883 [TBL] [Abstract][Full Text] [Related]
6. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt. Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819 [TBL] [Abstract][Full Text] [Related]
7. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy]. Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886 [TBL] [Abstract][Full Text] [Related]
8. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening. Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703 [TBL] [Abstract][Full Text] [Related]
11. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466 [TBL] [Abstract][Full Text] [Related]
12. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484 [TBL] [Abstract][Full Text] [Related]
13. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Kawatani T; Suou T; Tajima F; Ishiga K; Omura H; Endo A; Ohmura H; Ikuta Y; Idobe Y; Kawasaki H Eur J Haematol; 2001 Jul; 67(1):45-50. PubMed ID: 11553266 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641 [TBL] [Abstract][Full Text] [Related]
15. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327 [TBL] [Abstract][Full Text] [Related]
16. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785 [TBL] [Abstract][Full Text] [Related]
17. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359 [TBL] [Abstract][Full Text] [Related]
18. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. Montineri A; Nigro L; La Rosa R; Iacobello C; Larocca L; Cappello E; Fiumara PF; Di Raimondo F; Fatuzzo F J Clin Virol; 2011 Dec; 52(4):284-7. PubMed ID: 21906994 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206 [TBL] [Abstract][Full Text] [Related]
20. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. Idilman R; Arat M; Soydan E; Törüner M; Soykan I; Akbulut H; Arslan O; Ozcan M; Türkyilmaz AR; Bozdayi M; Karayalçin S; Van Thiel DH; Ozden A; Beksaç M; Akan H J Viral Hepat; 2004 Mar; 11(2):141-7. PubMed ID: 14996349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]